MedTrace Logo

A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting

NCT07709897 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2026-08-26

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy of HRS5580 for injection combined with palonosetron hydrochloride in the prevention of postoperative nausea and vomiting, and to explore the effective dose of HRS5580 for injection combined with palonosetron hydrochloride for the prevention of postoperative nausea and vomiting.

Conditions

  • Prevention of Postoperative Nausea and Vomiting

Interventions

DRUG

HRS5580 for injection combined with palonosetron hydrochloride;

HRS5580 for injection combined with palonosetron hydrochloride; low dose

DRUG

HRS5580 for injection combined with palonosetron hydrochloride

HRS5580 for injection combined with palonosetron hydrochloride; high dose

DRUG

HRS5580 for injection blank preparation combined with palonosetron hydrochloride

HRS5580 for injection blank preparation combined with palonosetron hydrochloride

Sponsors & Collaborators

  • Fujian Shengdi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-06
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07709897 on ClinicalTrials.gov